# Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction

> **NCT02837939** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Martin Janičko**

## Conditions studied

- Cirrhosis
- Liver Failure

## Interventions

- **DRUG:** Human derived Transfer factor
- **DRUG:** Aqua pro injectione 4ml ampules for subcutaneous injection

## Key facts

- **NCT ID:** NCT02837939
- **Lead sponsor:** Martin Janičko
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07
- **Primary completion:** 2025-07
- **Final completion:** 2025-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02837939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02837939, "Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT02837939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*